Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving…
Browsing: Non-Hodgkin Lymphoma
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known…
iFrame is not supported! Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does…
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known…
Alexey Danilov, MD, Ph.D., associate director of the Toni Stephenson Lymphoma Center at City of Hope speaks about the AACR…
Danelle James, M.D., M.A.S. of Pharmacyclics, an AbbVie company discusses IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström’s…
Mazyar Shadman, M.D., M.P.H. from Fred Hutchinson Cancer Research Center discusses A Phase I/II Study to Evaluate the Safety of…
Rajat Bannerji, MD, Ph.D. Chief, Section of Hematologic Malignancies at Robert Wood Johnson University Hospital and Rutgers Cancer Institute of…
Michael Wang, MD at MD Anderson discusses Kite Pharma’s FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed…
Caron Jacobson, MD of Dana Farber Cancer Institute @DanaFarber discusses the interim analysis of zuma-5 presented at this year’s virtual…
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin…
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin…
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin…
Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read…
Zachary Frosch, MD of Penn Medicine @PennMedicine explains that more prospective data is needed to validate stratification of molecular risk…
Zachary Frosch, MD of Penn Medicine @PennMedicine answers how stratification of molecular risk in aggressive b-cell lymphoma is validated. Diffuse…
Zachary Frosch, MD of Penn Medicine @PennMedicine discusses stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma…
Dr. James Bates, MD @JamesBatesMD of University of Florida @UF answers is this reflective of long term techniques on long…
Dr. James Bates, MD @JamesBatesMD of University of Florida @UF discusses long term outcomes in 10-year survivors of early-stage hodgkin…
Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers perspective on the latest…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC considers whether off-the-shelf CAR-T cell therapies are becoming a…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC offers impressions of the TRANSCEND-CLL-004 data investigating the use…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC discusses the three-year survival analysis of the ZUMA-1 study…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC tells us about the results of the ZUMA-2 study…
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses how combination therapies are evolving to unmet needs…
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses the unmet needs of the Phase 1/2 study…
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone tells us about the design and outcomes of the…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the results and findings…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence)…
Allison M. Winter, MD of @ClevelandClinic discusses comparative outcomes of relapsed follicular lymphoma patients treated with novel agents.
Timothy Illidge, MD, PhD of @OfficialUoM provides analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients…
Professor Simon Rule of Plymouth University Medical School discusses long term outcomes with ibrutinib versus the prior regimen.
Steven Horwitz, MD of @sloan_kettering discusses the phase 2 PRIMO study. _______ Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company),…
Brian Hill, MD of Cleveland Clinic @ClevelandClinic discusses KTE-X19
Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and…
Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and…
Rajat Bannerji, MD of @RutgersCancer provides an update on Phase I REGN1979. Â Â Â Â ash 2019, rutgers cancer,…
NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019…
Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 study –…
Ellen J. Kim, MD of @PennMedicine includes observations found in the PROVe Study. #EORTC19 _________ Dr. Ellen J. Kim, UPENN,…
Ellen J. Kim, MD of @PennMedicine addresses questions asked by colleagues including: how long are patients on therapy in the…
Ellen J. Kim, MD of @PennMedicine explains the PROVe Study on efficacy and quality of life (QoL) in patients with…
BOSTON–(BUSINESS WIRE)–Oct. 3, 2019– Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking…
ASH 2016 Page 4 Update on Antibody Therapies in Indolent Non-Hodgkin Lymphoma
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
CLL and non-hodgkin lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Should all HL patients be treated the same
Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses The Clinical…
Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Results Of The…
Steven Rosen, MD, from the City of Hope, Duarte, CA, discusses the remarkable quantity and quality of information on blood…